ARTV compared with ABOS: revenue, margins and what each company keeps, and the suppliers and customers both name

ARTVArtiva Biotherapeutics, Inc.

Mkt capRevenueRevenue

ABOSAcumen Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

ARTVArtiva Biotherapeutics, Inc.

ABOSAcumen Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

ARTV2 of 4 reports

0 of 2at or beyond implied

Reportimpliedrealized× implied

Oct 27 '26±76.2%▼−30.68%×0.40

Q2 FY26±35.1%▼−2.68%×0.08

ABOS2 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q3 FY26—▲+14.65%—

Q2 FY26±15.3%▲+1.62%×0.10

= impliedARTV realized, solidABOS realized, hatchedOne scale, both sides: full bar = 77%× = |realized| ÷ impliedSource: market data

ARTVArtiva Biotherapeutics, Inc.

4.20· pre 4.13· delayed

Mkt cap$204.8MRevenue$251,000Q1 FY24

ABOSAcumen Pharmaceuticals, Inc.

0.24· pre 0.23· delayed

Pre-marketNov 3 '26delayed

Mkt cap$17.3MRevenue—

Compare

Pre-marketNov 3 '26delayed

ARTVArtiva Biotherapeutics, Inc.

ABOSAcumen Pharmaceuticals, Inc.

4.20pre 4.13delayed

Price

0.24pre 0.23delayed

$204.8M

Mkt cap

$17.3M

Q1 FY24$251,000

Revenue

—

ARTV4.20vsABOS0.24Pre-marketNov 3 '26delayed